We keep going over a sale of Resverlogix, however, has Don ever mentioned an outright sale of the entire operation? As far as I know, he has not. Partnerships with Big Pharma, which he did state, the last of which was on Feb 4, 2021, Presentation as detailed on Slide 7. There he outlined a 5-year plan, BOM2, at a clinical cost of US$200M to be paid by the (unnamed) Pharma side in a partnership agreement. He opted against it and as we now know this has been refined in the Life Sciences Investor Forum of March 2022. The Clinical cost estimate is now $30-40 Million, a 50/50 split with S Hepalink. Presumably, Aversana was brought on board to assist in making this happen. This to me sounds a lot of like what Temsamany pointed to in his post. Going it alone!

Koo